FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2026692964> ?p ?o ?g. }

• W2026692964 endingPage "S19" @default.
• W2026692964 startingPage "S13" @default.
• W2026692964 abstract "SUMMARYObjective: To determine the impact of the lidocaine patch 5% on distinct pain qualities associated with osteoarthritis (OA) through use of the Neuropathic Pain Scale (NPS), an assessment tool designed to assess intensity of various pain qualities (i.e. sharp, dull).Patients and methods: Patients were enrolled in a prospective, open-label, non-randomized, parallel-group, 2-week study involving 8 clinical trial sites in the United States. Eligible patients had radiographic evidence of OA involving one or both knees and reported moderate-to-severe pain (despite prn or stable doses of analgesics) on the NPS at study enrollment. Patients on prn analgesics were discontinued from all analgesic regimens prior to study entry and received lidocaine patch 5% as monotherapy. Those on stable doses of analgesics were continued on their other analgesic regimens with no additions or dose alterations allowed other than the lidocaine patch 5% as add-on therapy. The lidocaine patch 5% was applied to the area of maximal pain, using no more than a total of 4 patches changed every 24 h. Effectiveness was measured by change from baseline to Week 2 in 4 composite measures of the NPS: NPS-10, NPS-4, NPS-8, and NPS-non-allodynia. Safety was assessed by adverse events (AEs), dermal assessment of application site(s), and skin sensory testing.Results: In the combined patient population (n = 100), 2 weeks of treatment with lidocaine patch 5% significantly improved all 4 NPS composite measures ( p < 0.001). Separate analyses by subgroups revealed significant improvements in all 4 composite measures for both the monotherapy group (n = 12; p < 0.01) and add-on therapy group (n = 88; p < 0.001). No treatment-related AEs were reported for the monotherapy group. In the add-on therapy group, 5 patients experienced mild-to-moderate treatment-related AEs.Conclusions: In patients with moderate-to-severe OA of the knee, 2 weeks of treatment with the lidocaine patch 5% significantly reduces the intensity of pain qualities as measured by all 4 NPS composite measures. Our results coincide with previously reported improvements in pain and physical function in the same patient population, as measured by the Western Ontario and McMaster Universities OA Index. Measuring the various qualities of pain appears to be a valid approach for assessing clinical outcomes in the treatment of OA pain. Pain measures such as the NPS can capture the multi-dimensional properties of a patient's pain experience and may offer clinicians the possibility to identify differential effects of analgesic treatments on various pain qualities associated with OA." @default.
• W2026692964 created "2016-06-24" @default.
• W2026692964 creator A5009823256 @default.
• W2026692964 creator A5016546686 @default.
• W2026692964 creator A5025969986 @default.
• W2026692964 creator A5033173589 @default.
• W2026692964 creator A5037522055 @default.
• W2026692964 date "2004-01-01" @default.
• W2026692964 modified "2023-09-27" @default.
• W2026692964 title "Lidocaine patch 5% and its positive impact on pain qualities in osteoarthritis: results of a pilot 2-week, open-label study using the Neuropathic Pain Scale" @default.
• W2026692964 cites W1967469609 @default.
• W2026692964 cites W1971005199 @default.
• W2026692964 cites W1995528018 @default.
• W2026692964 cites W2002178040 @default.
• W2026692964 cites W2006733509 @default.
• W2026692964 cites W2011487877 @default.
• W2026692964 cites W2026172623 @default.
• W2026692964 cites W2027008620 @default.
• W2026692964 cites W2057169976 @default.
• W2026692964 cites W2062159035 @default.
• W2026692964 cites W2065951014 @default.
• W2026692964 cites W2081977726 @default.
• W2026692964 cites W2094399103 @default.
• W2026692964 cites W2150882549 @default.
• W2026692964 cites W2159865397 @default.
• W2026692964 cites W2171317746 @default.
• W2026692964 cites W2318359287 @default.
• W2026692964 cites W2610860323 @default.
• W2026692964 cites W3028339224 @default.
• W2026692964 doi "https://doi.org/10.1185/030079904x12951" @default.
• W2026692964 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15563742" @default.
• W2026692964 hasPublicationYear "2004" @default.
• W2026692964 type Work @default.
• W2026692964 sameAs 2026692964 @default.
• W2026692964 citedByCount "73" @default.
• W2026692964 countsByYear W20266929642012 @default.
• W2026692964 countsByYear W20266929642013 @default.
• W2026692964 countsByYear W20266929642014 @default.
• W2026692964 countsByYear W20266929642015 @default.
• W2026692964 countsByYear W20266929642016 @default.
• W2026692964 countsByYear W20266929642017 @default.
• W2026692964 countsByYear W20266929642018 @default.
• W2026692964 countsByYear W20266929642019 @default.
• W2026692964 countsByYear W20266929642020 @default.
• W2026692964 countsByYear W20266929642021 @default.
• W2026692964 crossrefType "journal-article" @default.
• W2026692964 hasAuthorship W2026692964A5009823256 @default.
• W2026692964 hasAuthorship W2026692964A5016546686 @default.
• W2026692964 hasAuthorship W2026692964A5025969986 @default.
• W2026692964 hasAuthorship W2026692964A5033173589 @default.
• W2026692964 hasAuthorship W2026692964A5037522055 @default.
• W2026692964 hasConcept C126322002 @default.
• W2026692964 hasConcept C141071460 @default.
• W2026692964 hasConcept C14184104 @default.
• W2026692964 hasConcept C142724271 @default.
• W2026692964 hasConcept C168563851 @default.
• W2026692964 hasConcept C197934379 @default.
• W2026692964 hasConcept C204787440 @default.
• W2026692964 hasConcept C2776164576 @default.
• W2026692964 hasConcept C2777107010 @default.
• W2026692964 hasConcept C2780149897 @default.
• W2026692964 hasConcept C2780820201 @default.
• W2026692964 hasConcept C2908647359 @default.
• W2026692964 hasConcept C42219234 @default.
• W2026692964 hasConcept C71924100 @default.
• W2026692964 hasConcept C99454951 @default.
• W2026692964 hasConceptScore W2026692964C126322002 @default.
• W2026692964 hasConceptScore W2026692964C141071460 @default.
• W2026692964 hasConceptScore W2026692964C14184104 @default.
• W2026692964 hasConceptScore W2026692964C142724271 @default.
• W2026692964 hasConceptScore W2026692964C168563851 @default.
• W2026692964 hasConceptScore W2026692964C197934379 @default.
• W2026692964 hasConceptScore W2026692964C204787440 @default.
• W2026692964 hasConceptScore W2026692964C2776164576 @default.
• W2026692964 hasConceptScore W2026692964C2777107010 @default.
• W2026692964 hasConceptScore W2026692964C2780149897 @default.
• W2026692964 hasConceptScore W2026692964C2780820201 @default.
• W2026692964 hasConceptScore W2026692964C2908647359 @default.
• W2026692964 hasConceptScore W2026692964C42219234 @default.
• W2026692964 hasConceptScore W2026692964C71924100 @default.
• W2026692964 hasConceptScore W2026692964C99454951 @default.
• W2026692964 hasIssue "sup2" @default.
• W2026692964 hasLocation W20266929641 @default.
• W2026692964 hasLocation W20266929642 @default.
• W2026692964 hasOpenAccess W2026692964 @default.
• W2026692964 hasPrimaryLocation W20266929641 @default.
• W2026692964 hasRelatedWork W1001143193 @default.
• W2026692964 hasRelatedWork W168160429 @default.
• W2026692964 hasRelatedWork W1989512926 @default.
• W2026692964 hasRelatedWork W2034503869 @default.
• W2026692964 hasRelatedWork W2109271662 @default.
• W2026692964 hasRelatedWork W2120025615 @default.
• W2026692964 hasRelatedWork W2120511142 @default.
• W2026692964 hasRelatedWork W2145732412 @default.
• W2026692964 hasRelatedWork W2363295579 @default.
• W2026692964 hasRelatedWork W2188945369 @default.
• W2026692964 hasVolume "20" @default.
• W2026692964 isParatext "false" @default.

• next